Targeting autophagy in GBM therapy is still a matter of debate; autophagy induction has been observed in GBM in response to radio- and temozolomide-based therapy and even though a number of clinical trials aimed at inhibiting autophagy execution, mainly by CQ, have been launched, others directed to inhibiting mTOR pathway, and thus activating autophagy, are ongoing. This evidence concerns the gene MTOR and glioblastoma.